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a b s t r a c t
Aim: The prognosis for women with breast cancer has improved markedly over recent decades. However,
mortality from breast cancer remains high and, for those developing metastatic disease, curative therapy
is not possible. Here, we report the frequency and distribution of disease recurrence(s) in a large popu-
lation of women with AJCC stage II/III breast cancer and evaluate the impact of adjuvant treatment with
the bisphosphonate zoledronate on clinical outcomes.
Patients and methods: In the context of the AZURE study (ISRCTN7981382), 3359 patients with histolog-
ically confirmed stage II/III breast cancer were randomised to receive standard adjuvant
treatment ± zoledronate for five years. Patients were followed up for 10 years and all patients with recur-
rent disease in that time identified. The site of first recurrence, the first distant recurrence site(s) and
bone metastasis at any time were recorded and outcomes in the control and zoledronate treatment
groups compared. Survival after recurrence was also evaluated.
Results: In the study population as a whole, disease recurrence at a median follow-up of 117 months
occurred in 1010/3359 (30%) women with a relatively constant rate of disease relapse of around 3%
per year. 727 (72%) first recurrences were at distant sites, 178 locoregional (18%) and 105 (10%) both
locoregional and distant relapses occurred synchronously. Bone was the most frequent first recurrence
site occurring in 463 (14%) of all patients and was the only distant metastatic site in 265 (7.9%). 69%
of the control group who developed recurrent disease had bone metastases identified. Bone metastases
were more frequent in those with oestrogen receptor (ER) positive disease and recurrences overall, espe-
cially at visceral sites, were more likely with ER negative disease. Zoledronate reduced bone metastases in
both ER subgroups but increased the proportion with extra-skeletal metastases, particularly in women
who were not definitely postmenopausal at study entry. Adjuvant zoledronate also reduced bone metas-
tases after recurrence at an extra-skeletal site.
Conclusions: This analysis provides contemporary information on the frequency and pattern of recur-
rences after treatment for stage II/III breast cancer that may be of value in planning future adjuvant trials.
It confirms the ongoing importance of bone metastases and describes in detail for the first time the effects
of adjuvant zoledronate on the pattern of metastasis.
 2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The outcomes for women with breast cancer have improved
greatly over recent decades through a combination of earlier
diagnosis and more effective treatment, especially through the
incorporation of adjuvant systemic therapies alongside locoregional
treatments for stage I–III disease, as defined by the American Joint
Committee for Cancer (AJCC). However, considerable risks for breast
cancer recurrence and subsequent death remain, that are deter-
mined by a mixture of disease burden, tumour biology and the host
response. The majority of patients now present with stage I node
negative disease and have an excellent prognosis. Nevertheless, for
theminority of patients that present with AJCC stage II or III disease,
the risk of recurrence remains relatively high and, despite many
advances in the treatment of advanced breast cancer, metastatic
disease remains incurable. Efforts are ongoing to improve the
https://doi.org/10.1016/j.jbo.2021.100367
2212-1374/ 2021 The Authors. Published by Elsevier GmbH.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author at: Medical Oncology, Department of Oncology and
Metabolism, University of Sheffield, Sheffield, United Kingdom.
E-mail address: r.e.coleman@sheffield.ac.uk (R. Coleman).
Journal of Bone Oncology 28 (2021) 100367
Contents lists available at ScienceDirect
Journal of Bone Oncology
journal homepage: www.elsevier .com/ locate/ jbo
effectiveness of adjuvant systemic treatments with most
approaches focusing on treating the cancer itself, either non-
specifically through the use of adjuvant chemotherapy or by target-
ing the underlying biology of the disease with treatments targeted
against oestrogen and/or HER2/neu receptors [1]. Targeting the host
to prevent disease recurrence has been more challenging but adju-
vant bisphosphonates have been shown to reduce bone recurrence
and breast cancer mortality in the large postmenopausal subgroup
of women with early breast cancer [2] and are recommended for
use by a range of international treatment guidelines in this group
ofwomen if deemed to be at intermediate to high risk for breast can-
cer recurrence [3–5]. Theeffects of adjuvantbisphosphonates inpre-
menopausal women, especially the very young, remain uncertain
with suggestions fromanumber of trials that,while the risk for bone
metastases may be reduced, the spread of disease to other organs
appears to be increased and there is no overall benefit [2] and the
possibility for harm [6,7].
Several authors have explored breast cancer recurrence pat-
terns, trying to identify clinical and/or pathological parameters
that correlate with specific sites of relapse and clinical outcomes
but many of them report on patients treated many decades ago
and do not reflect the current population of women with the dis-
ease [8–10]. Follow-up was also often quite short and careful eval-
uation of sites of metastasis lacking. There is a need for information
on contemporary rates of disease recurrence and the distribution
of metastases in order to plan future suitably powered trials in
early breast cancer as well as to understand the impact of treat-
ments like bisphosphonates on the evolution of metastases across
the spectrum of women presenting with early breast cancer. In this
study we report on the frequency and patterns of metastasis over
the first 10 years after diagnosis and treatment with contemporary
adjuvant therapies and investigate the impact that adjuvant zole-
dronate, given within the context of the large AZURE trial (BIG
01/04) [11], had on the subsequent patterns of relapse according
to menopause status and the expression of oestrogen receptors
(ER).
AZURE patients were regularly reviewed during the 5-year
treatment phase and then annually for up to 10 years, or until
death, and during this period, both local and distant recurrences
have been prospectively recorded and the first site of any distant
recurrence and bone metastases at any time evaluated. Our study
aims to describe the frequency and pattern of breast cancer recur-
rence in the modern treatment era. The correlations between
menopausal status at the time of randomization, ER expression
and sites of relapse are also described, as well as the impact of
adjuvant zoledronate on clinical outcomes. Unusually, meta-
analysis of the adjuvant bisphosphonate trials showed a somewhat
greater effect on breast cancer mortality (HR = 0.82; 95%CI 0.73–
0.93) than on disease recurrence (HR = 0.86; 95%CI 0.78–0.94) [2]
suggesting that adjuvant bisphosphonates may influence survival
after recurrence as well as prevent a proportion of patients from
developing bone metastases. Therefore, as an additional explora-
tory endpoint, overall survival after BC recurrence was also evalu-
ated, according to the sites of first relapse and the addition of
zoledronate to standard adjuvant treatment.
2. Patients and methods
The AZURE trial was an academic, prospective, open label, ran-
domised, controlled phase III international, multicentre, parallel-
group trial. Eligibility has been reported previously [11] but, in
summary, patients had to have histologically confirmed invasive
breast cancer with either pathologically involved axillary lymph
node metastasis or a T3/T4 primary tumour (AJCC Stage II/III). Prior
complete resection of the primary tumour should have been
performed or had to be planned if patients were treated with
neoadjuvant chemotherapy. Patients were not eligible if there
was clinical or imaging evidence of distant metastases prior to
study entry or a history of prior cancer within the preceding five
years. Staging imaging tests were performed in accordance with
institutional protocols. All patients gave written informed consent.
Prior to randomisation, haematological, renal and hepatic function
tests were required.
Between September 2003 and February 2006, 3359 patients
with histologically confirmed stage II/III breast cancer were ran-
domised to receive standard adjuvant treatment ± zoledronate
for five years. The majority of the patients were recruited from
sites in the United Kingdom (n = 2710 [81%]) with others from Eire
(n = 247 [7.4%]), Australia (n = 226 [6.7%]), Spain (n = 107 [3.2%]),
Portugal (n = 32 [0.9%]), Thailand (n = 25 [0.7%]) and Taiwan (n = 13
[0.4%]). Surgical management, the use of adjuvant loco-regional
external beam radiotherapy and the selection of systemic adjuvant
treatments (chemotherapy and/or endocrine therapy) were
decided in accordance with standard protocols at each participat-
ing institution. The addition of trastuzumab to chemotherapy
was allowed in patients with Her-2 over-expressing tumours after
its regulatory approval for adjuvant use in 2005.
As also described previously [11], a minimisation process to
reduce possible imbalances in tumour and treatment characteris-
tics was used. This took into account the treating centre, the num-
ber of involved axillary lymph nodes, clinical tumour stage,
oestrogen receptor status, adjuvant systemic treatment modalities
and timing in relationship to surgery, concomitant use of statins
and the menopausal status of the patient at study entry. This
was categorised as either not definitely postmenopausal (NPM),
to include premenopausal women, those who would be considered
as perimenopausal as they were within 5 years of previous regular
menstruation, and those where menstrual status was difficult to
ascertain or unknown e.g. post-hysterectomy, or those considered
definitely postmenopausal (PM) in that greater than 5 years had
elapsed since last menses.
Patients randomised to receive zoledronate were given a 4 mg
intravenous infusion of zoledronate every 3–4 weeks for 6 cycles,
then every three months for 8 doses, followed by 5 cycles on a
six-monthly schedule for a total treatment duration of 5 years
(19 doses). Patients stopped zoledronate on completion of 5 years
treatment or following distant recurrence, unacceptable toxicity,
three consecutively missed treatments, patient request or physi-
cian recommendation. Continuation of study medication was rec-
ommended after loco-regional recurrence, and was at the
physician’s discretion following development of any new primary
cancer.
The follow-up schedule was similar in both control and zole-
dronate arms of the study and included clinical assessment,
adverse event monitoring and haematological, renal and hepatic
function test measurements. Routine follow-up imaging, other
than routine mammograms to screen for contralateral breast can-
cer and recurrence within a conserved treated breast, was not
mandated, with investigations for possible recurrence clinically
directed as deemed appropriate by the treating physician. Subjects
were followed up on an annual basis after completion of the 5-year
treatment phase (zoledronate or control) for disease recurrence,
death, skeletal related events and adverse events of interest.
All first recurrences were classified as loco-regional or distant
and the specific site(s) of all distant metastases recorded. If a
patient developed an extra-skeletal first distant recurrence, any
subsequent skeletal recurrence was collected as a post-distant
recurrence. Recurrences developing after development of a bone
metastasis were not systematically reported. Any two recurrence
events occurring within 30 days of each other were considered
as a single event to allow for the time necessary to perform the
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range of imaging tests (CT and/or MRI, bone scan) required to
restage a patient with potential recurrent disease. Dates of relapse
were backdated to the first clinical suspicion of recurrence rather
than the confirmation date. Loco-regional relapses were classified
by site: ipsilateral breast, chest wall, loco-regional lymph nodes
or multiple sites. First distant relapse sites were classified as skele-
tal and/or extra-skeletal, with the latter being further categorized
as visceral (liver, lung, pleura, central nervous system, adrenal
gland, bowel, kidney, pancreas) or soft tissue (distant nodes,
uterus, ovaries, peritoneum, mediastinum, skin, subcutaneous tis-
sue) recurrences. To allow for interpretation of patients with mul-
tiple extra-skeletal metastatic sites and avoid double counting,
non-osseous metastases were ascribed a hierarchy of likely clinical
importance of brain +/ other sites, liver +/ other sites except
brain, lung/pleura +/ other sites except for brain or liver metas-
tases and soft tissue +/ other sites except for brain, liver and
lung/pleura metastases.
Recurrence information was confirmed by on site or telephone-
based review of clinical notes and imaging tests in 91% of patients.
Recurrence dates and site classification were double-checked by
two independent operators SD and SN); in case of disagreement,
data were reanalysed with the lead author (RC) until all discrepan-
cies were eliminated.
2.1. Statistical analysis
Descriptive statistics were used to show the patterns of recur-
rence. Risk ratios (RR) were used to compare subgroups. All analy-
ses should be considered exploratory and as such no P values were
ascribed to differences between groups. Survival analyses were
investigated using Kaplan-Meier survival curves and hazard ratios
(HR) with 95% confidence intervals (CI) for these data are
presented.
3. Results
Key patient characteristics are shown in Table 1 reflecting a
population of patients at intermediate to high risk of recurrence
due to lymph node involvement or larger tumour size. Additional
patient characteristics can be found in earlier reports of the AZURE
trial. [11–12] The patient and tumour characteristics were very
similar across the two treatment groups. 3207/3359 (95%) of
patients received adjuvant chemotherapy with or without endo-
crine treatment depending on ER status. 1776/2634 (67%) of
women with ER positive tumours received an aromatase inhibitor
at some time following study entry; 665/780 (85%) and 1111/1854
(60%) who were PM and NPM at study entry respectively. Fewer
than 5% of premenopausal women received ovarian suppression
as part of their adjuvant endocrine treatment programme. Because
of the timeframe when patients were recruited, HER2 status was
unknown in 1693/3359. (50%) of patients. Of the 1666 with known
HER2 status at study entry, 415 (25%) were HER2 positive and 277
(67%) of these women received adjuvant trastuzumab. In addition,
a further 169 patients, not known to be HER2 positive at study
entry, received trastuzumab at some time during follow-up.
3.1. Natural history of stage II/III breast cancer
In the study population as a whole, disease recurrence at a med-
ian follow-up of 117 months (interquartile range 70–120 months)
Table 1
Allocation Standard Treatment Alone Standard treatment + ZOL.
Number Percent Number Percent
Lymph node involvement 32 1.9 30 1.8
0 nodes involved
One - three nodes involved 1033 61.6 1042 62.0
=> four nodes involved 607 36.2 604 35.9
Unknown involvement 6 0.4 5 0.3
Tumour stage 523 31.2 542 32.2
T1
T2 867 51.7 850 50.6
T3 228 13.6 228 13.6
T4 59 3.5 58 3.5
TX 1 0.1 3 0.2
ER status 1315 78.4 1318 78.4
ER positive
ER negative 356 21.2 350 20.8
ER unknown 7 0.4 13 0.8
PR status 699 41.7 725 43.1
Positive
Negative 424 25.3 382 22.7
Unknown/missing 555 33.1 574 34.1
HER2 status 223 13.3 192 11.4
Positive
Negative 604 36.0 648 38.5
Unknown/missing/not measured 851 50.7 841 50.0
Histological grade 141 8.4 146 8.7
1
2 708 42.2 731 43.5
3 787 46.9 765 45.5
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Fig. 1. Distribution and number of disease recurrences at 10 years of follow-up in the AZURE study of women with stage II/III breast cancer. DR, distant recurrences; RR
overall recurrences; FU, follow up.
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has occurred in 1010/3359 (30%) women with a relatively constant
rate of disease relapse of around 3% per year. 727/1010 (72%) first
recurrences were at distant sites, 178/1010 were locoregional
(18%) and in 105/1010 (10%) both locoregional and distant relapses
occurred synchronously (Fig. 1). Bone was the most frequent first
recurrence site occurring in 463/3359 (14%) of all patients and
was the only distant metastatic site in 265/3359 (7.9%).
Although zoledronate had no impact on recurrence rates overall
(control 508 patients, zoledronate 502: HR = 0.92, 95% CI
0.81–1.05) there were, as reported previously, [11–13] effects of
adjuvant zoledronate within specific patient subgroups that are
discussed below. As a result of these study treatment effects, the
control group provides the most reliable data on the natural his-
tory of early breast cancer (Table 2). 508/1678 (30%) of control
patients experienced disease recurrence (368/508 [73%] distant,
83/508 [16%] locoregional and 57/508 [11%] both distant and
locoregional).
Bone was the most frequent metastatic site, occurring as the
site of first recurrence in 259/1678 control patients (51% of
relapses) and the first site of distant recurrence in 278/450 (62%)
patients with a distant recurrence including those with a first dis-
tant relapse in bone after a locoregional recurrence. Bone metas-
tases occurred at any time during the 10 years of follow up in
352/508 patients (69%) with disease recurrence. 113/259 (44%)
patients with first recurrence in bone had synchronous first metas-
tases at other distant sites (viscera in 77, soft tissues in 11 and both
viscera and soft tissues in 25 patients) while, in 144/1678 (8.6%) of
all control patients and 144/259 (56%) of those with bone metas-
tases, the disease appeared to be confined to bone as the only dis-
tant metastatic site with a further 7 patients developing bone only
disease following a locoregional relapse. The annual rate of devel-
oping bone only metastases in this population did not exceed 1%.
Extra-skeletal sites were the first site of recurrence in 166/1678
(10%). Table 3 shows the first site(s) of these extra-skeletal
relapses, both at single sites and in combination with other
extra-skeletal sites. In the control group, first distant recurrence
in the brain only was seen in 26 (1.5%), in the liver only in 68
(4.1%), in the lung and/or pleura in 68 (4.1%) and in soft tissues
in 38 (2.3%) of the 1678 patients in the control group.
3.2. Impact of ER on patterns of disease recurrence
The recurrences by ER status in the control group of patients are
shown in Tables 4 and 5. More relapses occurred in patients with
ER disease (RR = 1.43: ER 143/356 [40%]; ER+ 363/1322
[28%]). Locoregional recurrences (RR = 3.62: ER 41/356 [12%];
ER+ 42/1322 [3.2%]) and extra-skeletal recurrences, both with
(RR = 2.84: ER 83/356 [23%]; ER+ 107/1322 [8.1%]) and without
(RR = 2.05: ER 59/356 [17%]; ER+ 107/1322 [8.1%]) synchronous
bone metastases were more frequent in patients with ER disease.
Bone only metastatic disease was associated with the presence of
ER+ disease (RR = 1.79: ER+ 125/1322 [9.5%]; ER 19/356 [5.3%]).
ER status had greatest impact on the development of brain metas-
tases, both as the only site of recurrence and in combination with
other metastatic sites (RR = 3.30 (21/118 [ER 18%]; ER+ 18/334
[5.4%]).
The rate of recurrence in the early years was faster in women
with ER tumours. After 24 months, invasive disease recurrence
had occurred in 27% of ER but only 8% of ER+ tumours. By
60 months 42% of ER and 21% of ER+ women had developed
recurrent disease. Thereafter the rates of recurrence were less
than 1% and 3–4% per year from ER and ER+ disease respectively.
3.3. Impact of menopausal status on patterns of disease recurrence
The risks for recurrence were similar across the menopausal
subgroups (RR = 0.91: NPM 339/1156 [29%]; PM 167/522 [32%]).
Table 5 shows these data including the 86 distant recurrences that
developed after a local recurrence. Somewhat surprisingly first
recurrence in bone (with or without other metastatic sites)
appeared to be slightly more common (RR = 1.17) in NPM patients
(198/1156 [17%]) compared with the PM subgroup (80/522 [15%]).
However, this probably reflects the slightly higher proportion of
ER disease in PM patients (25%) recruited to the trial compared
with the NPM subgroup (20%).
3.4. Effects of adjuvant zoledronate on disease outcomes
Although zoledronate had no statistically or clinically signifi-
cant effect on recurrence rates overall (Table 5), it did reduce the
proportion of patients developing bone metastases as the first site
of recurrence both as the only metastatic site (RR = 0.72: zole-
dronate 104/1681 [6.2%]; control 144/1678 [8.6%]) and in combi-
nation with other metastatic sites (RR = 0.78: zoledronate
202/1681 [12%]; control 259/1678 [15%]). Bone recurrences were
reduced in both menopausal subgroups and in those with either
ER or ER+ disease. However, extra-skeletal recurrences were
more frequent in patients receiving zoledronate, particularly in
NPM patients (RR 1.48: zoledronate 155/1678 [9.2%]; control
105/1681 [6.3%]) and those with ER disease (RR 1.21: zoledronate
201/1681 [12%]; control 166/1678 [9.9%]).
Table 2
Type and site of first recurrence overall and by treatment allocation.
Type and first site of recurrence Recurrences All patients
% All first recurrences [%]. Distant recurrence Control Zoledronate
n 3359 n = 1010 n = 832 1678 1681
All first recurrences 1010 [30%] [100%] NA 508 [30%] 502 [30%]
Distant +/ locoregional recurrence 832 [25%] [83%] [100%] 425 [25%] 407 [24%]
Distant recurrence only 727 [22%] [72%] [87%] 368 [22%] 359 [21%]
Distant + locoregional recurrence 105 [3%] [10%] [12%] 57 [3.4%] 48 [2.9%]
Locoregional +/ distant 281 [8%] [28%] NA 138 [8.2%] 143 [8.5%]
Locoregional recurrence 178 [5%] [18%] NA 83 [4.9%] 95 [5.7%]
Bone +/ other 461 [14%] [46%] [56%] 259 [15%] 202 [12%]
Bone only recurrence 248 [7.4%] [25%] [30%] 144 [8.6%] 104 [6.2%]
Viscera only 232 [7%] [23%] [28%] 99 [5.9%] 133 [7.9%]
Soft tissue +/ other 135 [4%] [13%] [16%] 67 [4.0%] 68 [4.0%]
Distant recurrence after locoregional recurrence 86/178 (48%) 36/83 (43%) 50/95 (53%)
Bone recurrence after extrakeletal recurrence 146/586 (25%) 74/285 (26%) 72/301 (24%)
Bone recurrence after locoregional recurrence 44/178 (25%) 19/83 (23%) 25/95 (26%)
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Table 3
Sites of first distant relapse by oestrogen receptor (ER) status and menopausal status. PM, postmenopausal; NPM, not postmenopausal; Zol, zoledronate.




Control Zol All Control Zol All Control Zol All Control Zol All Control Zol
n = 1678 n = 1681 n = 707 n = 356 n = 350 2633 n = 1322 n = 1331 2318 n = 1156 n = 1162 n = 1041 n = 522 n = 519




























Bone +/ other distant site 507 [57%] 278 [62%] 229 [52%] 83 [35%] 53 [45%] 30 [24%] 420 [65%] 225 [67%] 195 [62%] 361 [58%] 198 [66%] 163 [43%] 146 [53%] 80 [53%] 66 [52%]
Bone only 266 [30%] 151 [33%] 115 [26%] 37 [15%] 23 [19%] 13 [11%] 230 [35%] 128 [38%] 102 [32%] 196 [32%] 111 [37%] 85 [28%] 72 [26%] 40 [27%] 32 [25%]
Bone + soft tissue 28 [3.2%] 14 [3.1%] 14 [3.2%] 6 [2.5%] 4 [3.4%] 2 [1.6%] 22 [3.4%] 10 [3.0%] 12 [3.8%] 20 [3.2%] 10 [3.3%] 10 [3.2%] 8 [2.9%] 4 [2.7%] 4 [3.2%]
Bone + viscera 144 [16%] 82 [19%] 62 [14%] 3 [1.3%] 21 [18%] 9 [7.3%] 117 [18%] 61 [18%] 56 [18%] 99 [16%] 55 [18%] 44 [14%] 48 [17%] 27 [18%] 21 [17%]
Bone + viscera + soft tissue 69 [7.8%] 31 [6.9%] 38 [8.7%] 11 [4.6%] 5 [4.2%] 6 [4.9%] 51 [7.9%] 26 [7.8%] 25 [7.8%] 46 [7.4%] 22 [7.3%] 24 [7.8%] 18 [6.5%] 9 [6.0%] 9 [7.1%]
Brain +/ any other distant
site
76 [8.6%] 39 [8.7%] 37 [8.4%] 41 [17%] 21 [18%] 20 [16%] 35 [5.4%] 18 [5.4%] 17 [5.4%] 52 [8.4%] 26 [8.6%] 26 [8.4%] 29 [11%] 12 [8.0%] 17 [13%]
Brain 52 [5.9%] 26 [5.8%] 26 [5.9%] 31 [13%] 15 [13%] 16 [13%] 21 [3.2%] 11 [3.3%] 10 [3.2%] 37 [6.0%] 19 [6.3%] 18 [5.8%] 16 [5.8%] 6 [4.0%] 10 [8.0%]
Brain + any other distant
site
24 [2.7%] 13 [2.9%] 11 [2.5] 10 [4.2%] 6 [5.3%] 4 [3.3%] 14 [2.2%] 7 [2.1%] 7 [2.2%] 15 [2.4%] 7 [2.3%] 8 [2.6%] 13 [4.7%] 6 [4.0%] 7 [5.6%]
Liver +/ other than brain 273 [31%] 131 [29%] 142 [32%] 65 [27%] 34 [29%] 31 [25%] 208 [32%] 97 [29%] 111 [35%] 187 [30%] 86 [29%] 101 [33%] 86 [31%] 45 [30%] 41 [33%]
Liver 150 [17%] 68 [15%] 82 [18%] 38 [16%] 21 [18%] 17 [14%] 111 [17%] 47 [14%] 65 [21%] 108 [17%] 47 [16%] 61 [20%] 42 [15%] 21 [14%] 21 [17%]
Liver + other 123 [14%] 63 [14%] 60 [13%] 27 [11%] 13 [12%] 14 [11% 95 [15%] 50 [15%] 46 [15%] 79 [13%] 39 [13%] 40 [13%] 44 [16%] 24 [16%] 20 [16%]
Lung/pleura +/ other
than brain or liver
159 [18%] 82 [18%] 77 [17%] 58 [24%] 24 [21%] 34 [28%] 101 [16%] 58 [17%] 43 [14%] 104 [17%] 50 [17%] 54 [17%] 56 [20%] 32 [21%] 24 [19%]
Lung/pleura 117 [13%] 68 [15%] 49 [11%] 41 [17%] 19 [17%] 22 [18%] 76 [12%] 49 [15%] 27 [8.6%] 75 [12%] 42 [14%] 33 [11%] 42 [15%] 26 [17%] 16 [13%]
Lung/pleura + other 42 [4.7%] 14 [3.1%] 28 [6.4%] 17 [7.1%] 5 [4.4%] 12 [9.8%] 25 [3.9%] 9 [2.7%] 16 [5.1%] 29 [4.7%] 8 [2.7%] 21 [6.8%] 14 [5.1%] 6 [4.0%] 8 [6.3%]
Soft tissue +/ other than
brain. liver, lung, pleura
86 [9.7%] 38 [8.4%] 48 [11%] 25 [10%] 8 [7.1%] 17 [14%] 61 [9.4%] 30 [9.0%] 31 [9.8%] 60 [9.7%] 23 [7.6%] 37 [12%] 26 [9.4%] 15 [10%] 11 [8.7%]
Viscera not specified 30 [3.4%] 11 [2.4%] 19 [4.3%] 16 [6.7%] 8 [7.1%] 8 [6.5%] 14 [2.2%] 3 [0.89%] 11 [3.5%] 22 [3.5%] 5 [1.7%] 17 [5.5%] 8 [2.9%] 6 [4.0%] 2 [1.6%]

























































Although the numbers are quite small, prior treatment with
zoledronate also appeared to influence the development of bone
metastases after recurrence of disease at an extra-skeletal site
(RR = 0.76: zoledronate 72/211 [34%], control 74/166 [45%]) of
patients relapsing first at an extra-skeletal distant site.
As reported previously, [6] overall survival was similar in the
zoledronate and control groups (adjusted hazard ratio
[HR] = 0.92; 95% CI 0.81–1.05) with a trend in favour of treatment
with zoledronate in PM patients (HR = 0.840 95%CI 0.67–1.04). In
this study we evaluated the impact of adjuvant zoledronate on sur-
Table 4
Impact of oestrogen receptor (ER) and menopausal status on patterns of recurrence in the control arm.
First site[s] of recurrence All control patients ER ve patients ER +ve/unknown patients
1678 n = 356 n = 1322
Number of recurrences [%] Number of recurrences [%] Number of recurrences [%]
All first recurrences 508 [30%] 143 [40%] 363 [28%]
Distant +/ local 433 [26%] 102 [29%] 321 [24%]
Distant recurrence only 368 [22%] 83 [23%] 285 [22%]
Distant + local Recurrence 55 [3.3%] 19 [5.3%] 36 [2.7%]
Bone only distant recurrence 144 [8.6%] 19 [5.3%] 125 [9.5%]
Extraskeletal distant recurrence +/ bone 279 [17%] 83 [23%] 196 [15%]
Extraskeletal recurrence only 166 [10%] 59 [17%] 107 [8.1%]
Local +/ distant 138 [8.2%] 60 [17%] 78 [5.9%]
Local Recurrence 83 [4.9%] 41 [12%] 42 [3.2%]
Postmenopausal status Pre/peri and uncertain menopausal status
All Control Control
n = 1678 n = 522 n = 1156
Number of recurrences [%] Number of recurrences [%] Number of recurrences [%]
All first recurrences 508 [30%] 167 [32%] 339 [29%]
Distant +/ local 423 [25%] 136 [26%] 287 [25%]
Distant recurrence only 368 [22%] 116 [22%] 252 [22%]
Distant + local Recurrence 55 [3.3%] 20 [3.8%] 35 [3.0%]
Bone only distant recurrence 144 [8.6%] 36 [6.9%] 108 [9.3%]
Extraskeletal distant recurrence +/ bone 279 [17%] 100 [19%] 179 [15%]
Extraskeletal recurrence only 166 [10%] 61 [12%] 105 [9.1%]
Local +/ distant 138 [8.2%] 51 [9.8%] 87 [7.5%]
Local Recurrence 83 [4.9%] 31 [5.9%] 52 [4.5%]
Table 5
Interaction between treatment arm and both oestrogen receptor (ER) and menopausal status on patterns of recurrence.
First site[s] of recurrence ER ve patients ER +ve/unknown patients
All Control Zol All Control Zol













All first recurrences 287 [41%] 143 [40%] 144 [41%] 715 [27%] 363 [28%] 352 [26%]
Distant +/ local 212 [30%] 102 [29%] 110 [31%] 612 (23%) 321 [24%] 291 [22%]
Distant recurrence only 175 [25%] 83 [23%] 92 [26%] 546 [21%] 285 [22%] 261 [20%]
Distant + local Recurrence 37 [5.2%] 19 [5.3%] 18 [5.1%] 66 [2.5%] 36 [2.7%] 30 [2.3%]
Bone only distant recurrence 31 [4.4%] 19 [5.3%] 12 [3.4%] 217 [8.2%] 125 [9.5%] 92 [7.0%]
Extraskeletal distant recurrence +/ bone 181 [26%] 83 [23%] 98 [28%] 395 [15%] 196 [15%] 199 [15%]
Extraskeletal recurrence only 145 [21%] 59 [17%] 86 [25%] 222 [8.4%] 107 [8.1%] 115 [8.7%]
Local +/ distant 114 [16%] 60 [17%] 52 [15%] 169 [6.4%] 78 [5.9%] 91 [6.9%]
Local Recurrence 77 [11%] 41 [12%] 34 [9.7%] 103 [3.9%] 42 [3.2%] 61 [4.6%]
Postmenopausal status Pre/peri and uncertain
menopausal status
All Control Zol All Control Zol













All first recurrences 313 [30%] 167 [32%] 136 [26%] 699 [30%] 339 [29%] 360 [31%]
Distant +/ local 252 [24%] 136 [26%] 116 [22%] 572 [25%] 287 [25%] 285 [25%]
Distant recurrence only 221 [21%] 116 [22%] 105 [20%] 500 [22%] 252 [22%] 248 [21%]
Distant + local Recurrence 31 [3.0%] 20 [3.8%] 11 [2.1%] 72 [3.1%] 35 [3.0%] 37 [3.2%]
Bone only distant recurrence 66 [6.3%] 36 [6.9%] 30 [5.8%] 182 [7.9%] 108 [9.3%] 74 [6.4%]
Extraskeletal distant recurrence +/ bone 186 [18%] 100 19%] 86 [17%] 394 [17%] 179 [15%] 215 [19%]
Extraskeletal recurrence only 117 [11%] 61 [12%] 56 [11%] 260 [11%] 105 [9.1%] 155 [13%]
Local +/ distant 82 [7.9%] 51 [9.8%] 31 [6.0%] 199 [8.9%] 87 [7.5%] 112 [9.6%]
Local Recurrence 51 [4.9%] 31 [5.9%] 20 [3.9%] 127 [5.5%] 52 [4.5%] 75 [6.5%]
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vival after disease recurrence. Fig. 2 shows zoledronate had no
effect on duration of survival after disease recurrence, either over-
all or in those specifically developing bone metastases.
4. Discussion
In this descriptive analysis of the natural history of women with
stage II/III breast cancer diagnosed between 2003 and 2006, the
pattern of metastases with contemporary locoregional and adju-
vant systemic treatments has been evaluated. Follow-up was per-
formed systematically according to a clinical trial protocol
throughout the 10 years and the site(s) of first recurrence and
any subsequent development of bone metastases identified. Dis-
ease recurrence occurred in 30% of patients, illustrating the rela-
tively low annual rate of around 3% per year in what would
traditionally have been considered a population of patients at high
risk for recurrence. 22% of patients had a distant recurrence, 5.3%
an isolated locoregional relapse and 3.1% synchronous distant
and locoregional recurrences at 10 years.
The treatment of patients reported in this analysis is represen-
tative of those presenting today other than with regard to the use
of adjuvant HER2 targeted treatment, and may be of assistance to
those designing adjuvant trials in helping with power calculations
for likely recurrence rates. Because of the time frame of recruit-
ment, evaluation of HER2 status was performed in only half of
the patients. About 250/1692 patients with unknown HER2 status
could be estimated to have had HER2+ disease and thus been eligi-
ble for adjuvant trastuzumab. In patients with HER2+ disease
untreated with trastuzumab and with similar risk factors for
relapse to our population, the proportion experiencing disease
recurrence within 10 years of diagnosis in the control arms of
the adjuvant trastuzumab trials was about 40% [13]. Based on
the benefits seen in 10-year outcomes with the addition of trastu-
zumab reported in these trials, and subsequent refinement in HER2
targeted adjuvant therapy strategies [14,15], around 20 recur-
rences (4%) in each treatment group might be expected to have
been preventable with current HER2 targeted treatment
approaches, thereby potentially reducing the 10-year rate of dis-
ease recurrence rate further from the 30% we report here to around
26%.
As expected [16], the proportion of patients developing disease
recurrence was higher in those with ER disease compared to
those with ER+ tumours. Visceral, and especially brain metastases,
were more frequent from ER tumours and bone metastases were
associated with ER+ disease. Interactions between ER and HER2
status on patterns of recurrence could not be assessed reliably
due to missing HER2 status in one half of patients in the trial.
Locoregional recurrence was also more frequent in those with
ER disease. The rates and distribution of disease recurrence in
this study were similar in the PM and NPM subgroups. Pre-
menopausal women are typically at higher risk of relapse due to
the higher proportion with ER disease [17] but, in this study,
the proportions of patients with ER disease were somewhat
higher in the PM subgroup, likely reflecting patient selection for
inclusion in a clinical trial of an intravenous treatment and the very
high proportion in this study considered by their treating oncolo-
gist to require adjuvant chemotherapy.
As reported previously [12], adjuvant zoledronate did not
improve disease outcomes for the overall study population, a find-
ing that is consistent across the many trials evaluated by the Early
Breast Cancer Trialists Collaborative Group (EBCTCG) meta-
analysis [2]. However, treatment did reduce first recurrence of
disease in bone, both as the only site of recurrence and occurring
synchronously with other distant sites. This beneficial effect on
bone metastases was seen in both ER and ER+ tumours and in
NPM as well as PM women. Extra-skeletal distant metastases
however were more frequent in patients treated with adjuvant
zoledronate, especially in NPM patients who would be expected
to have higher levels of reproductive hormones in the bone
microenvironment that zoledronate specifically targets. Indeed,
in women aged less than 40 years, we have previously shown that
this increase in risk for extra-skeletal metastases was associated
with a 67% (95%C.I. 16–140%) increased risk of breast cancer death
[6]. Metastasis is a highly complex, non-linear process with evi-
dence, at least from animal models, that re-seeding by circulating
tumour cells (CTC) after development of metastasis in one organ
may occur at other distant and/or loco-regional sites [18]. Our
observation that bone metastases after first recurrence at an
extra-skeletal site were reduced in patients treated with zole-
dronate in the adjuvant setting suggests possible protection from
re-seeding of CTC released from non-osseus sites.
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Fig. 2. Survival after recurrence by treatment group.
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Potential mechanisms underpinning the relationships between
disease outcomes with adjuvant zoledronate and menopausal sta-
tus and tumour biology are being actively studied. The relationships
between menopause and outcome have been recapitulated in ani-
mal models, with zoledronate reducing metastases in young mice
subjected to oophorectomy but not in those undergoing a sham
operation [19]. More recently, the same group of researchers has
evaluated the effects of zoledronate on the immune response to
breast cancer and found that zoledronate causes a decrease in
tumour suppression within the tumour microenvironment. This
appeared to be mediated by a decrease in Treg infiltration and
activity, an increase in macrophage polarisation towards an antitu-
mour phenotype and an increase in cd T cell antigen recognition
[20]. These immune effects of a bisphosphonate may, at least in
part, explain the difference in outcomes between adjuvant bispho-
sphonates and the evenmore potent inhibitor of osteoclast activity,
denosumab. This agent failed to improve disease outcomes in stage
II/III breast cancer [21] even though its effects on bone cell function
are similar to a bisphosphonate, perhaps because it does not have
the same immune modulating effects as the bisphosphonates.
In terms of tumour biology, a number of biomarkers have been
identified that, in addition to providing prognostic information
[22], may also provide predictive information on likely response
to adjuvant zoledronate and facilitate patient selection for treat-
ment beyond the current criteria of recurrence risk and menopau-
sal status [4–6]. These include immunohistochemical staining of
the primary tumour for a number of bone homing peptides, includ-
ing macrophage-capping protein (CAPG) and PDZ domain–contain-
ing protein member 1 (GIPC1) [23] and fluorescence in-situ
hybridisation (FISH) analysis of the primary tumour for copy num-
ber of the transcription factor MAF [24]. MAF appears particularly
promising as a predictive marker with benefits from zoledronate
restricted to the 80% of patients with normal levels of MAF expres-
sion (MAF-) and occurring irrespective of menopausal status while,
in those patients with amplification of MAF (MAF+), zoledronate
treatment was associated with a marked excess of extra-skeletal
metastases and worse overall survival [6,25]. A schema illustrating
the possible interactions between zoledronate treatment, meno-
pausal status and tumour biology is shown in Fig. 3.
Survival after recurrence was unaffected by prior treatment
with bisphosphonates despite the previously reported beneficial
impact on skeletal complications after recurrence, especially those
with relapse in bone [26]. Median survival after recurrence was
only 22 months and it is salutary to note that, for those women
who do develop recurrent disease, despite current adjuvant sys-
temic and locoregional recurrences, survival after relapse has
changed little over recent decades [27]. Recent developments
beyond trastuzumab for those with HER2+ disease [28] and the
use of CDK4 inhibitors in ER+ disease [29], neither of which were
in routine use for the treatment of patients included in this popu-
lation of patients, are improving survival but only by a matter of
months and breast cancer remains the leading cause of cancer
death in women in North America and Europe [30].
In conclusion, patients with stage II/III breast cancer can antic-
ipate a relatively good prognosis with a 10-year recurrence rate of
less than 30%. Bone remains the most common site for metastasis
and, just as it did 3 decades ago [10], occurs in 70% of patients with
advanced breast cancer. Adjuvant treatment with zoledronate
changes the distribution pattern of metastases, reducing bone
relapses but not recurrences at other sites and, in women with pre-
menopausal levels of reproductive hormones and/or adverse
tumour characteristics may promote disease spread to visceral
sites. Novel bone targeted strategies are needed to further improve
disease outcomes and reliable biomarkers identified to optimise
patient selection for bone targeted treatments.
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UNFAVOURABLE PREDICTIVE BIOMARKERS 
ZOLEDRONATE LESS BENEFICIAL
Fig. 3. Schema representing interactions between menopausal status (microenvironment levels of oestrogen), tumour associated biomarkers and treatment with
zoledronate. Use of adjuvant zoledronate in combination with premenopausal levels of reproductive hormones and unfavourable biomarker expression such as amplification
of the transcription factor MAF is associated with adverse disease outcomes. Conversely, use of adjuvant zoledronate in combination with postmenopausal levels of
reproductive hormones and favourable tumour biomarkers such as normal levels of MAF or/and expression of CAPG/GIPC1 is associated with improved disease outcomes
[23,25].
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